spacer
home > ebr > winter 2003 > the future of biomanufacturing
PUBLICATIONS
European Biopharmaceutical Review

The Future of Biomanufacturing

In my previous article, I reviewed the recent history of biopharmaceutical manufacturing, and the factors that have driven the industry to be the size and shape that it is today. In this article, I will be looking at the emerging trends and technologies, and considering the influence that they will have on biopharmaceutical manufacturing in the future.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sharon Grimster, Director of Westerly Projects Ltd

Sharon Grimster started her career working on clinical trials at Guys Hospital Medical School in London. She then moved to Celltech, working in research for four years prior to taking up various management positions within contract manufacturing. Sharon subsequently managed preclinical and clinical development programmes for both new chemical entities and biological entities. Following the mergers with Chiroscience and Medeva, Sharon became Head of Biologics Manufacturing Development. She left Celltech in 2002 and is now a Director of Westerly Projects Ltd, a consultancy company offering development services to the biopharmaceutical industry globally.

spacer
Sharon Grimster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement